Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Earnings Per Share Diluted of $2.33 per share for the year ending 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +206.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.56 (loss) per share | Q3 2020: $2.18 (loss) per share | Q1 2021: $1.71 (loss) per share | Q2 2021: $1.61 (loss) per share | Q3 2021: $1.72 (loss) per share | Q1 2022: $2.00 (loss) per share | Q2 2022: $2.29 (loss) per share | Q3 2022: $3.32 (loss) per share | Q1 2023: $1.40 (loss) per share | Q2 2023: $2.21 (loss) per share | Q3 2023: $1.15 per share | Q1 2024: $0.52 (loss) per share | Q2 2024: $0.13 (loss) per share | Q3 2024: $0.87 (loss) per share | Q1 2025: $0.14 (loss) per share | Q2 2025: $0.51 (loss) per share | Q3 2025: $1.84 per share.
- Over the full 7 years of available data (2019 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Earnings Per Share Diluted has grown by 128.7%.
- Historical annual values: Fiscal year 2025: $2.33 per share | Fiscal year 2024: $2.18 (loss) per share | Fiscal year 2023: $3.52 (loss) per share | Fiscal year 2022: $9.30 (loss) per share | Fiscal year 2021: $7.20 (loss) per share | Fiscal year 2020: $7.46 (loss) per share | Fiscal year 2019: $8.11 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: